Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone Therapy

Name *

Email *

Phone *

Program *

State *

Age (30+ only) *

Confirm Age Over 30 * Yes

Confirm Live In USA * Yes

* Required

If you are an American adult man or women, serious about considering Bio-Identical Hormone Replacement Therapy treatments using any of the following: HGH injections, Testosterone injections, Sermorelin Injections and would like to discuss your options with a U.S. Board certified Physician Expert Specialist in Integrative, Internal, Endocrinology, regenerative and Longevity medicine, with more than 20 years of clinical experience, trained by the American Academy of Anti-Aging Medicine (A4M) world health net , then contact me below now.

Be sure to leave when and what, the best time and day is to reach you by phone. All of our hormone injections are Made in the USA and shipped to you from within the United States, that means the highest quality prescription available in the world.

You must be an American Citizen, over the age of 30, to qualify. We serve all fifty United States.

RALEIGH, N.C., May 21, 2020 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals announced today that the United States Patent and Trademark Office (USPTO) has issued two critical patents related to its lead asset, Kyzatrex®*. Kyzatrex® is an oral Testosterone Replacement Therapy (TRT) that uses an innovative formulation to improve effectiveness and safety.

These allowed claims will provide strong IP protection to December 2030, over 8 years of potential commercial runway. They supplement Marius Pharmaceuticals’ already robust global patent portfolio for Kyzatrex®, which includes granted patents in the European Union, Canada, China, Taiwan, Japan, New Zealand, and other key markets, and pending applications in India, and the US. Marius Pharmaceuticals’ patent portfolio includes filings that extend protection to 2033, with the potential to extend protection out to 2040.

The allowed claims protect Kyzatrex ®, a progressive formula configured to boost bioavailability and provide a favorable pharmacokinetic (PK) profile compared to other therapeutic choices. Om Dhingra, Chief Executive Officer of Marius stated “This innovation is truly exceptional as we have created a formulation with a unique PK profile which we believe drives important clinical significance.”

Marius Pharmaceuticals’ Chief Financial Officer Shalin Shah said “We are very pleased to strengthen the intellectual property portfolio for Kyzatrex® and excited that it has tremendous potential to be a differentiated and unique option in the TRT space. We are also drawing a line in the sand between a new treatment paradigm and old testosterone therapies.”

Marius Pharmaceuticals has recently completed its pivotal Phase 3 study for Kyzatrex® and intends to submit its New Drug Application (NDA) to the Food & Drug Administration (FDA).

About Kyzatrex®

Kyzatrex® is an experimental therapy for the treatment of primary and secondary hypogonadism (congenital or acquired). Testosterone is a crucial hormone that plays a crucial role in human growth and development and a wide range of other functions including metabolic and cardiovascular. Sources estimate that 15 million men in the United States suffer from hypogonadism, but only approximately 10% are currently treated. The co-morbidities of men suffering from hypogonadism are also a significant burden on patients and the healthcare system, these include Type 2 Diabetes and other serious chronic conditions.

Currently, marketed treatments are dominated by painful injections and messy topical applications with transference risk. Kyzatrex® is an orally administered therapy, which avoids those drawbacks. Market research points to 93% of patients indicating they would ask their physician about Kyzatrex® and more than half would consider a switch from their current regimen.

About Marius Pharmaceuticals

Marius pharmaceuticals is a cutting-edge biopharma company focusing on treating widespread conditions that have been triggered primarily through Androgen deficiency. Our pipeline consists of assets focused on inflammation while our commercial arm is at the forefront of data science technologies core to the commercialization of our lead asset Kyzatrex®.

*Kyzatrex is a tentative Tradename currently under review with the FDA

Reference:

https://www.globenewswire.com/news-release/2020/05/21/2036889/0/en/Marius-Pharmaceuticals-Announces-Issuance-of-Two-Key-Patents-Protecting-its-Proprietary-Oral-Testosterone-Therapy.html

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *

Your State *

Select Age (30+ only) *

Confirm Age Over 30 * Yes

Confirm Live In USA * Yes

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.
Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.